Northern Trust
ACRV icon

Northern Trust’s Acrivon Therapeutics ACRV Stock Holding History

Northern Trust’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68K Sell
48,902
-14,816
-23% -$25.8K ﹤0.01% 4189
2025
Q4 		$154K Buy
63,718
+21,552
+51% +$46.9K ﹤0.01% 4052
2025
Q3 		$76.3K Sell
42,166
-4,610
-10% -$6.48K ﹤0.01% 4196
2025
Q2 		$55.7K Sell
46,776
-62,249
-57% -$85.4K ﹤0.01% 4212
2025
Q1 		$221K Sell
109,025
-8,298
-7% -$44.7K ﹤0.01% 3910
2024
Q4 		$706K Buy
117,323
+11,925
+11% +$86.7K ﹤0.01% 3532
2024
Q3 		$738K Sell
105,398
-8,655
-8% -$68.2K ﹤0.01% 3455
2024
Q2 		$662K Buy
114,053
+6,303
+6% +$50.8K ﹤0.01% 3402
2024
Q1 		$770K Buy
107,750
+27,601
+34% +$128K ﹤0.01% 3412
2023
Q4 		$394K Buy
80,149
+7,427
+10% +$39.2K ﹤0.01% 3622
2023
Q3 		$695K Buy
72,722
+4,044
+6% +$46.7K ﹤0.01% 3415
2023
Q2 		$890K Sell
68,678
-1,073
-2% -$13K ﹤0.01% 3400
2023
Q1 		$885K Buy
+69,751
New +$1.17M ﹤0.01% 3260

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's ACRV Position: Q1 2026 in Review

Northern Trust reduced its Acrivon Therapeutics (ACRV) stake by 23% in Q1 2026, selling an estimated $25.8K and leaving 48,902 shares worth $68K. The position accounts for ﹤0.01% of the portfolio, ranked #4189.

Northern Trust first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $890K in Q2 2023. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Northern Trust held 48,902 shares of Acrivon Therapeutics worth $68K as of Q1 2026.
  • Northern Trust sold 14,816 Acrivon Therapeutics shares in Q1 2026, an estimated $25.8K.
  • Acrivon Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4189 holding.
  • Northern Trust first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Northern Trust's Acrivon Therapeutics position peaked at $890K in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.